Boehringer expands production site in Greece for new medicine Ruchika Sharma14 Jan 2024 9:00 AM ISTIngelheim: Boehringer Ingelheim, a research-driven biopharmaceutical company, has announced a further expansion and upgrade of its plant in...
Boehringer Ingelheim, 3T Biosciences enter into second partnership for cancer immunotherapies Ruchika Sharma7 Jan 2024 10:00 AM ISTIngelheim: Boehringer Ingelheim and 3T Biosciences have announced they have entered into a new strategic collaboration and licensing agreement...
Boehringer Ingelheim partners with Ribo to develop new treatments for people with liver diseases Ruchika Sharma3 Jan 2024 1:53 PM ISTIngelheim: Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB (Ribo) have announced a collaboration with Boehringer Ingelheim to...
Boehringer Ingelheim receives approval for Senvelgo in Europe for diabetic cats Ruchika Sharma24 Nov 2023 3:30 PM ISTFeline diabetes mellitus is a metabolic disorder which occurs when a cat has insufficient levels of, or an abnormal response to insulin.
Boehringer Ingelheim expands immuno oncology portfolio with acquisition of bacterial cancer therapy specialist T3 Pharma Ruchika Sharma24 Nov 2023 1:30 PM ISTGermany: Boehringer Ingelheim has announced the acquisition of privately-held T3 Pharmaceuticals AG, a clinical stage Swiss biotech company, for an...
Aldosterone synthase inhibitor shows promise in CKD trial: Boehringer Ingelheim Ruchika Sharma5 Nov 2023 2:30 PM ISTGermany: Boehringer Ingelheim has announced promising 14-week Phase II data for BI 690517, a novel selective aldosterone synthase inhibitor...
Boehringer Ingelheim, Zealand Pharma announce initiation of 3 phase III trials investigating Survodutide for obesity Ruchika Sharma8 Oct 2023 3:30 PM ISTIngelheim: Boehringer Ingelheim and Zealand Pharma A/S have announced the initiation of three Phase III trials investigating survodutide (also known...
Boehringer unveils 81 percent discounted biosimilar of AbbVie Humira Ruchika Sharma4 Oct 2023 3:30 PM ISTUntil recently, Humira was the world's biggest-selling prescription drug. It had sales of USD 21.2 billion in 2022.
Boehringer Ingelheim latest to sue US over drug price negotiation plan Ruchika Sharma22 Aug 2023 3:00 PM ISTType 2 diabetes treatment Jardiance, which Boehringer shares with US drugmaker Eli Lilly, is considered among the most likely drugs to be chosen for...
Boehringer Ingelheim to advance Survodutide into 3 global Phase III studies in obesity Ruchika Sharma20 Aug 2023 10:00 AM ISTGermany: Boehringer Ingelheim has announced it will advance survodutide, its glucagon/GLP-1 receptor dual agonist, into three registrational Phase III...
USFDA accepts application for Boehringer Ingelheim OFEV for children, adolescents aged 6-17 years old with fibrosing interstitial lung disease Ruchika Sharma27 July 2023 1:30 PM ISTRidgefield: Boehringer Ingelheim has announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application...
Eli Lilly- Boehringer Ingelheim Jardiance gets European Commission nod to treat adults with CKD Ruchika Sharma26 July 2023 4:30 PM ISTIngelheim: The European Commission (EC) has approved Jardiance (empagliflozin) for the treatment of adults with chronic kidney disease (CKD),...
